The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Apr 2014
Randomized Controlled Trial Multicenter Study Comparative StudyOnce-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
As new members of a drug class are developed, head-to-head trials are an important strategy to guide personalised treatment decisions. We assessed two glucagon-like peptide-1 receptor agonists, once-weekly albiglutide and once-daily liraglutide, in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. ⋯ GlaxoSmithKline.